PSMB8

Migration, Crosslink

📖

PSMB8

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-psmb8

📖 Wiki Page

gene1370 wordssynced 2026-04-02

PSMB8 - Proteasome Subunit Beta 8

Introduction

...

PSMB8 - Proteasome Subunit Beta 8

Introduction

Mermaid diagram (expand to render)

PSMB8 encodes the proteasome subunit beta type-8, also known as LMP7 (Large Multifunctional Protease 7). This gene produces the catalytic subunit of the immunoproteasome, which plays a critical role in protein homeostasis, antigen presentation, and cellular stress responses. PSMB8 is highly relevant to neurodegenerative diseases due to its involvement in the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS), which clears misfolded and aggregated proteins that accumulate in Alzheimer's disease, Parkinson's disease, and related disorders. [@ferrington2012]

<div class="infobox infobox-gene"> [@kincaid2012]
<div class="infobox-header">Gene Information</div> [@mishto2015]
<div class="infobox-row"> [@liu2012]
<div class="infobox-label">Gene Symbol</div> [@chen2021]
<div class="infobox-value">PSMB8</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Proteasome Subunit Beta 8</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">6p21.33 (MHC class II region)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/5698" target="_blank">5698</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://omim.org/entry/177060" target="_blank">177060</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000240065</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/P28062" target="_blank">P28062</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Aliases</div>
<div class="infobox-value">LMP7, beta5i, proteasome subunit LMP7</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">Alzheimer's Disease, Parkinson's Disease, CANDLE Syndrome, Amyotrophic Lateral Sclerosis</div>
</div>
</div>

Overview

PSMB8 is a member of the proteasome family and encodes the β5i subunit, which is primarily expressed in immune cells and becomes the catalytically active component of the immunoproteasome. The immunoproteasome is a specialized form of the 26S proteasome that generates antigenic peptides for MHC class I presentation and handles oxidative stress-induced protein damage more efficiently than the constitutive proteasome[@ferrington2012].

In the brain, PSMB8 is expressed in [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes), and [neurons](/entities/neurons), where it plays essential roles in:

Clearance of oxidized and misfolded proteins
Regulation of inflammatory responses
Maintenance of neuronal protein homeostasis
Cellular stress adaptation

Dysregulation of PSMB8 and the immunoproteasome has been implicated in the pathogenesis of several neurodegenerative diseases, where proteasome dysfunction contributes to the accumulation of toxic protein aggregates.

Protein Structure and Function

Domain Organization

PSMB8 encodes a 276-amino acid protein that undergoes proteolytic processing to form the mature catalytic subunit. The protein contains:

N-terminal propeptide: Removed during maturation

Catalytic core: β5i subunit with chymotrypsin-like activity

Thr1 active site: N-terminal threonine residue for proteolysis

Catalytic Activity

PSMB8 exhibits chymotrypsin-like (β5), caspase-like (β1), and trypsin-like (β2) activities when incorporated into the immunoproteasome. The immunoproteasome generates peptides with hydrophobic C-termini that are optimized for MHC class I binding[@kincaid2012].

Role in the Immunoproteasome

The immunoproteasome (20S proteasome with PSMB8, PSMB9/LMP2, and PSMB10/LMP10 subunits) replaces the constitutive catalytic subunits (β5, β1, β2) and is induced by interferon-γ. In the brain, immunoproteasome expression increases under:

Neuroinflammatory conditions
Oxidative stress
Protein aggregation stress
Aging

Signaling Pathways and Interactions

Ubiquitin-Proteasome System

PSMB8 functions as the catalytic core of the immunoproteasome within the ubiquitin-proteasome system (UPS):

Polyubiquitin chain recognition: Substrates tagged with K48-linked ubiquitin chains are recognized

19S regulatory particle binding: ATPases unfold and translocate substrates

20S core particle proteolysis: PSMB8 cleaves substrates into 3-22 amino acid peptides

Peptide release: Generated peptides are released for further processing

NF-κB Signaling

The immunoproteasome regulates [NF-κB](/entities/nf-kb) signaling through:

Degradation of IκBα (inhibitor of NF-κB)
Processing of NF-κB precursors (p100, p105)
Generation of IkBζ for transcriptional regulation

Interferon Signaling

PSMB8 expression is directly regulated by:

IFN-γ via STAT1/IRF1 binding to promoter elements
TNF-α through NF-κB-dependent pathways
Type I interferons (IFN-α/β)

Brain Expression and Cellular Distribution

Expression in Neural Cells

| Cell Type | Expression Level | Functional Implications |
|-----------|-----------------|------------------------|
| Microglia | High | Immune surveillance, antigen presentation |
| Astrocytes | Moderate | Neuroinflammation, protein clearance |
| Neurons | Low-Moderate | Synaptic protein turnover, stress response |
| Oligodendrocytes | Low | Myelin protein homeostasis |

Regional Distribution

PSMB8 is expressed throughout the brain with higher levels in:

[Hippocampus](/brain-regions/hippocampus) (CA1, dentate gyrus)
Cerebral [cortex](/brain-regions/cortex) (layer 5 pyramidal neurons)
Substantia nigra (dopaminergic neurons)
Cerebellum (Purkinje cells)

This pattern overlaps with brain regions vulnerable to neurodegeneration in AD and PD.

Disease Associations

Alzheimer's Disease

Association: PSMB8 immunoproteasome activity is altered in AD brain

Mechanisms:

Amyloid-β peptides induce immunoproteasome expression in microglia
[Tau](/proteins/tau) pathology is associated with reduced proteasome activity
Oxidative stress increases PSMB8 as an adaptive response
Impaired proteasome function contributes to tau and amyloid accumulation

Evidence: Studies show increased PSMB8 mRNA and protein in AD prefrontal cortex and hippocampus, particularly in microglia surrounding amyloid plaques[@mishto2015].

Parkinson's Disease

Association: PSMB8 dysfunction implicated in α-synucleinopathy

Mechanisms:

[α-Synuclein](/proteins/alpha-synuclein) aggregates inhibit proteasome activity
PSMB8 upregulation as compensatory response
Failure of protein clearance leads to neuronal death
LRRK2 mutations affect immunoproteasome function

Evidence: Post-mortem studies show elevated PSMB8 in substantia nigra of PD patients, with highest expression in microglia containing Lewy bodies.

Amyotrophic Lateral Sclerosis (ALS)

Association: Proteasome dysfunction in ALS pathogenesis

Mechanisms:

Mutant SOD1 aggregates impair proteasome activity
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology associated with reduced proteasome function
PSMB8 upregulation in astrocytes and microglia
[C9orf72](/entities/c9orf72) mutations affect protein homeostasis pathways

CANDLE Syndrome

Autoinflammatory Disease: PSMB8 is causally mutated in CANDLE (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) syndrome[@liu2012]

Autosomal recessive mutations cause loss of proteasome function
Results in interferon-driven inflammation
Features: skin lesions, lipodystrophy, fever, organ inflammation

Therapeutic Implications

Proteasome Modulators

| Agent | Mechanism | Development Stage |
|-------|-----------|------------------|
| Bortezomib | Reversible proteasome inhibitor | Approved for multiple myeloma |
| Carfilzomir | Irreversible proteasome inhibitor | Approved for multiple myeloma |
| ONX-0914 (PR-957) | Selective PSMB8/LMP7 inhibitor | Preclinical/clinical |
| MG-132 | Broad proteasome inhibitor | Research tool |

Neurodegeneration Therapeutics

Proteasome activators: Small molecules that enhance proteasome activity

Immunoproteasome-selective modulators: Target brain inflammation

Combination approaches: Proteasome enhancement with [autophagy](/entities/autophagy) induction

Gene therapy: Viral vector-mediated PSMB8 expression

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier) penetration
Selectivity for immunoproteasome over constitutive proteasome
Balancing protein clearance with potential toxicity

Animal Models

Knockout Mice

Psmb8−/− mice show:

Deficient antigen presentation
Increased susceptibility to viral infection
Accumulation of oxidized proteins under stress
Altered cytokine responses

Transgenic Models

Neuronal PSMB8 overexpression: Enhanced protein clearance
Astrocyte-specific PSMB8: Modulated neuroinflammation
Humanized mice: Better modeling of human immunoproteasome

Phenotypic Observations

Age-related protein aggregate accumulation
Enhanced neuroinflammation in models
Improved cognitive function with PSMB8 overexpression

Genetic Variants

Single Nucleotide Polymorphisms (SNPs)

| SNP | Function | Disease Association |
|-----|----------|---------------------|
| rs2071543 | Coding variant | Altered catalytic activity |
| rs1319501 | Promoter variant | Modified expression |
| rs2530409 | Intron variant | Linked to autoimmune disease |

Disease-Specific Variants

CANDLE syndrome: Loss-of-function mutations (R152X, G137W)
Alzheimer's disease: Potential protective variants
Parkinson's disease: Risk variants under investigation

Research Directions

Emerging Areas

Selective immunoproteasome inhibitors: For autoimmune and inflammatory diseases

Brain-penetrant proteasome modulators: For neurodegenerative diseases

PSMB8 biomarker development: Cerebrospinal fluid measurements

Gene therapy approaches: AAV-mediated expression

Unanswered Questions

Why do certain neuronal populations show vulnerability to proteasome dysfunction?
How does immunoproteasome activity change with normal aging?
Can proteasome enhancement slow disease progression?
What determines the balance between proteasome and autophagy?

Background

The study of Psmb8 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[NCBI Gene: PSMB8](https://www.ncbi.nlm.nih.gov/gene/5698)
[UniProt: PSMB8](https://www.uniprot.org/uniprot/P28062)
[Ensembl: PSMB8](https://www.ensembl.org/Homo_sapiens/ENSG00000240065)
[OMIM: PSMB8](https://omim.org/entry/177060)

References

Ferrington DA, Gregerson PS, Immunoproteasome: Novel biomarker and therapeutic target in neurodegenerative diseases (2012)

Kincaid EZ, et al, Mice lacking immunoproteasome subunits LMP7 and LMP10 develop normally but are defective in CD8+ T cell responses (2012)

Mishto M, et al, Immunoproteasome expression is induced in the brains of Alzheimer's disease patients (2015)

Liu Y, et al, Mutations in the proteasome subunit β8 gene (PSMB8) cause CANDLE syndrome (2012)

Chen Q, et al, Proteasome-mediated degradation of SNCA and toxicity of alpha-synuclein aggregates (2021)

Pathway Diagram

The following diagram shows the key molecular relationships involving PSMB8 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

PSMB8

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-psmb8
kg_node_id	PSMB8
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c5b0f6cf866a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-psmb8'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PSMB8

PSMB8 - Proteasome Subunit Beta 8

Introduction

PSMB8 - Proteasome Subunit Beta 8

Introduction

Overview

Protein Structure and Function

Domain Organization

Catalytic Activity

Role in the Immunoproteasome

Signaling Pathways and Interactions

Ubiquitin-Proteasome System

NF-κB Signaling

Interferon Signaling

Brain Expression and Cellular Distribution

Expression in Neural Cells

Regional Distribution

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

CANDLE Syndrome

Therapeutic Implications

Proteasome Modulators

Neurodegeneration Therapeutics

Challenges

Animal Models

Knockout Mice

Transgenic Models

Phenotypic Observations

Genetic Variants

Single Nucleotide Polymorphisms (SNPs)

Disease-Specific Variants

Research Directions

Emerging Areas

Unanswered Questions

Background

See Also

External Links

References

Pathway Diagram

💬 Discussion